A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Recruiting

Phase 3

Sponsor:

Aura Biosciences

Code:

NCT06007690

Conditions

Choroidal Melanoma

Indeterminate Lesions

Uveal Melanoma

Ocular Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bel-sar

Suprachoroidal Microinjector

Infrared Laser

Sham Infrared Laser

Sham Microinjector

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information